The Horizon Europe awarded a Cancer Mission Grant to JaxBio Technologies.The project, named SANGUINE, awarded approximately €8.5M, where €1.7M is allocated for JaxBio. The scope of this project is the development of a diagnostic test for the early detection and screening of hematological malignancies based on the JaxBio technology. For this project, we recruited a comprehensive and strong team of experts from across Europe, 

specializing in clinical, technological, and social fields.

Among our partners: Tel Aviv University (IL), Palacky University (CZ), Inter-Array (FZMB) as an expert in microarrays development and manufacturing.
Four medical centers that will provide valuable clinical input and samples, and will implement the JaxBio test in parallel to the standard of care: Vilnius University Hospital (LT), University Hospital Olomouc (CZ), National and Kapodistrian University of Athens, Tel Aviv Sourasky Medical Center (IL).

Additional partners are PerdictBy, which will design an approach for increasing screening rates, and the European Cancer Organization (ECO). The latter is the largest and most connected cancer patient organization in the EU. This will allow access to healthcare professionals, patients, and researchers, aiming to distribute and implement the test.

The proposal received exceptionally high scoring, highlighting a vote of confidence in the technology by the scientific community.